^
    Back
    Association details:
    Biomarker:BRAF T1799A
    Cancer:Thyroid Gland Carcinoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Biochem Biophys Res Commun
    Title:

    The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204)

    Excerpt:
    Thus, this study has confirmed that the BRAF(T1799A) mutation confers cancer cells sensitivity to PLX4032…
    DOI:
    10.1016/j.bbrc.2010.12.088